With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.
Into a 40-mL round-bottom flask, was placed 4-(4- [[2-(4-chlorophenyl)-4,4-dimethylcyclohex- i-en-i – ylj methyljpiperazin- 1 -yl)-2- [ i4-oxa-2,4, iO-triazatricyclo [7.5 .0.0?[3 ,7j jtetradeca- 1 (9),2,5,7- tetraen-iO-yljbenzoic acid (50 mg, 0.08 mmol, 1 equiv), DCM (3 mL), 3-nitro-4-[[(oxan-4- yl)methyljaminojbenzene-i-sulfonamide (25.2 mg, 0.08 mmol, 1.00 equiv), EDCI (30.6 mg, 0.16 mmol, 2 equiv), DMAP (39.0 mg, 0.32 mmol, 4 equiv). The resulting solution was stirred for overnight at 25 degrees C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (10:1). The crude product was purified by Flash-Prep-HPLC with the following conditions (IntelFlash-i): Column, Ci8 reversed phase column; mobile phase, Water (1OMMOL/L NH4HCO3+0.05%NH3.H20) and CH3CN (20.0% CH3CN up to 90.0% in 30 mm); Detector, UV 220 nm. This resulted in 19.1 mg (25.90%) of 4-(4- [[2-(4-chlorophenyl)-4,4-dimethylcyclohex- i-en-i -ylj methyljpiperazin- 1 -yl)N-(3-nitro-4-[[(oxan-4-yl)methylj aminojbenzenesulfonyl)-2- [ i4-oxa-2,4, 10- triazatricyclo [7.5 .0.0?[3,7j jtetradeca- 1 (9),2,5,7-tetraen- iO-yljbenzamide as a yellow solid. LCMS: (ES, m/z): M+i=923, R,T= 3.463 mm. The measurements of the retention were done with a reversed phase column (C 18). Shimadzu LCMS 2020; 50*3.0 Agilent Poroshell HPH-Ci8, 2.7um; Eluent A: water (0.05 % ammonia water); Eluent B: Acetonitrile; linear gradient from 5 % acetonitrile to 95 % acetonitrile in 7.0 minutes; Oven temperature 40 C; flow: 1.5 mL/min. ?H NMR (300 MHz, DMSO-d6,ppm) 11.91 (s, iH), 11.26 (s, iH), 8.56 (s, iH), 8.47 (d, J= 2.1 Hz, iH), 7.61 (d, J = 9.0 Hz, iH), 7.48 (d, J = 9.2 Hz, iH), 7.37 (d, J = 8.3 Hz, 2H), 7.20 (s, iH), 7.07 (d, J = 8.3 Hz, 2H), 6.99 – 6.83 (m, 2H), 6.76 (d, J = 29.2 Hz, 2H), 6.14 (s, iH), 4.21 (s, 2H), 3.85 (d, J = 9.3 Hz, 2H), 3.52 (s, 2H), 3.30 – 3.14 (m, 8H), 2.79 (s, iH), 2.23 (d, J = 20.0 Hz, 5H), 1.99 (s, 4H), 1.85 (s, iH), 1.61 (d, J= 11.3 Hz, 2H), 1.42 (s, 2H), 1.25 (s, 2H), 1.03-0.79 (m, 6H). The measurements of the NMR spectra were done with Bruker Avancelli HD300MHz with a probe head of BBOF.
1228779-96-1, 1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; NEWAVE PHARMACEUTICAL INC.; CHEN, Yi; LOU, Yan; (108 pag.)WO2019/40550; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics